- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
Volume 2013 (2013), Article ID 514914, 4 pages
No Association between FCγR3B Copy Number Variation and Susceptibility to Biopsy-Proven Giant Cell Arteritis
1Rheumatology Department, The Queen Elizabeth Hospital, Woodville South, SA 5011, Australia
2The Health Observatory, Discipline of Medicine, The University of Adelaide, Adelaide, SA 5005, Australia
3Discipline of Medicine, The University of Adelaide, Adelaide, SA 5005, Australia
4Centre for Eye Research, Royal Victorian Eye and Ear Hospital, University of Melbourne, East Melbourne, VIC 3002, Australia
5Lions Institute, University of Western Australia, Nedlands, WA 6009, Australia
Received 26 June 2013; Accepted 21 July 2013
Academic Editor: Bruce M. Rothschild
Copyright © 2013 Emma Dunstan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Objective. To determine the relationship between FCGR3B gene copy number variation (CNV) and biopsy proven giant cell arteritis (GCA). Methods. FCGR3B CNV was determined in 139 Australian biopsy proven GCA patients and 162 population matched controls, using a duplex qPCR assay and RNase P as the reference gene. Copy number was determined using Copy Caller software (v.1.0, Applied Biosystems, USA). CNV genotypes were classified into 3 groups (<2, 2, 3+) for analysis purposes, and analysis was performed using logistic regression. Results. All GCA patients had a positive temporal artery biopsy, and the most common presenting symptoms were visual disturbance and temporal headache. The mean age of patients at biopsy was 74 years (range 51–94) and 88/139 (63%) were female. The frequency of low (<2) FCGR3B copy number was comparable between GCA patients (%) and controls (%), as was the frequency of high (3+) FCGR3B copy number (15/130 (10.8%) in GCA patients versus 13/162 (8.0%) in controls). Overall there was no evidence that FCGR3B CNV frequencies differed between GCA patients and controls (, , ). Conclusion. FCGR3B CNV is not associated with GCA; however, replicate studies are required.
Giant cell arteritis (GCA), also known as temporal arteritis, is a systemic inflammatory vasculitis which primarily affects medium to large extracranial arteries of the head and neck and can result in stroke and blindness. GCA typically affects people aged over 50 years and incidence rates increase with advancing age, peaking around 80 years of age . GCA is 2-3 times more likely to affect females and is more commonly diagnosed in Caucasians than in any other ethnic background with the highest incidence observed in populations of Scandinavian descent .
The pathogenesis of GCA is not understood, although environmental, infectious, and genetic risk factors have been implicated. Familial aggregation and established associations with HLA-DR4 provide evidence for a genetic component to GCA [3–5]. Multiple genetic association studies have been performed on a number of immune response genes. However, the majority of these studies have been performed on a single GCA cohort from north-western Spain and, to date, have failed to confirm any additional genetic associations.
One gene of interest is Fc gamma receptor 3B (FCGR3B) which exhibits gene copy number variation (CNV), an important source of quantitative genetic variation. Copy number variation is a departure from the normal diploid number of genes () which may arise through gene duplication and deletion events. An increasing number of CNVs have been characterised in the human genome with implications for both evolution and disease susceptibility . CNV has been well characterised in the FCGR gene cluster on chromosome 1q23. This cluster carries five highly homologous genes that encode for low-affinity receptors for IgG-complexed antigens, which are expressed widely throughout the haematopoietic system. These low-affinity Fc-gamma receptors are involved in the regulation of a multitude of innate and adaptive immune responses, with implications for both response to infection and susceptibility to autoimmunity .
CNV in the FCGR3B gene is of particular interest. FCGR3B is expressed almost exclusively on neutrophils , and there is a clear correlation between gene copy number and FCGR3B cell surface expression, neutrophil adherence to IgG-coated surfaces, and immune complex uptake . Further, multiple studies have identified low FCGR3B CN (i.e., <2 copies) as a risk factor for systemic autoimmune diseases, such as systemic lupus erythematosus [9–11], rheumatoid arthritis [12, 13], primary Sjögren’s syndrome [10, 11], and scleroderma , which is interpreted in terms of the important role that Fc receptors play in the clearance of immune complexes. In contrast, given the importance of neutrophil activation in vascular inflammation , it is plausible that high FCGR3B copy number may in fact predispose to receptor-mediated neutrophil activation and therefore vasculitis.
Previous studies in relation to FCGR3B CNV and vasculitis are inconclusive. Associations have been reported with both low  and high  copy number, whilst other studies have not identified such an association (reviewed in ). We have also previously reported that FCGR3B CNV is not a risk factor for Behcet’s disease  in Iranian patients. The aim of this study was to evaluate the association between FCGR3B CNV and biopsy-proven GCA in an Australian patient cohort.
2. Materials and Methods
One hundred and thirty-nine Australian biopsy-proven GCA patients were recruited through the South Australian Giant Cell Arteritis Registry and the Royal Victorian Eye and Ear Hospital. This study has ethics approval from the Queen Elizabeth Hospital, Royal Adelaide Hospital, Repatriation General Hospital and Flinders Medical Centre in South Australia, and the Royal Victorian Eye and Ear Hospital in Victoria, and all participants provided written, informed consent. A total of 162 population controls (53% female, median age 56 years) were used for comparison.
2.2. FCGR3B Copy Number Typing
Genomic FCGR3B copy number was assessed using a custom TaqMan quantitative real-time PCR (qPCR) method, as previously described [11, 12, 17]. Briefly, a duplex TaqMan copy number assay was performed, using FCGR3B-specific primers (Applied Biosystems, Hs04211858, FAM-MGB dual-labeled probe) and RNase P (Applied Biosystems, product 4403326, VIC-TAMRA dual-labeled probe) as the reference assay. The assay was performed according to the manufacturer’s instructions, and PCR reactions were run on an Applied Biosystems 7300 Real-Time PCR machine. All samples were tested in triplicate, and fluorescence signals were normalised to ROX. Copy number was determined using Copy Caller software (v.1.0, Applied Biosystems, USA), and results were accepted only when calling confidence was >80% and ΔCq standard deviation between replicates was <0.20.
2.3. Statistical Analysis
Analysis of FCGR3B CNV was performed using logistic regression. Effect sizes were reported as odds ratios (OR) with 95% confidence intervals (95% CI).
The demographic characteristics of the GCA patients are displayed in Table 1. All patients had a positive temporal artery biopsy. The mean age of patients at biopsy was 74 years (range 51–94) and 88/139 (63%) were female.
Five different copy number variant genotypes were observed in this study, corresponding to 0, 1, 2, 3, 4 FCGR3B copies in a diploid individual. Because 0 and 4 copies were infrequent, genotypes were classified into 3 groups (< 2, 2, 3+) for analysis purposes. The most common FCGR3B gene copy number was 2 (normal diploid number) which was identified in 139/162 (86%) of controls and 114/138 (83%) of GCA patients (Table 2). There was no evidence that the overall distribution of FCGR3B CNV genotypes differed significantly between GCA patients and controls (global , , ) nor was there any evidence of a specific difference between GCA patient and controls for low (<2, ) or high (3+, ) FCGR3B copy number (Table 2).
Whilst an association between FCGR3B low copy number (<2) and susceptibility to systemic autoimmune diseases is well established, with potential mechanisms relating to receptor clearance of immune complexes, and perhaps the most plausible hypothesis in relation to vasculitis is that high FCGR3B copy number may predispose via increased receptor-mediated neutrophil activation. This is the first study to examine the relationship between FCGR3B CNV and susceptibility to biopsy-proven GCA, and we report no evidence of an association with either high or low copy number.
Previous studies have reported intriguing, but conflicting, relationships between FCGR3B copy number and vasculitis in the context of different diseases. Both low and high FCGR3B copy number (<2) have been associated with anti-neutrophil cytoplasmic antibody-associated systemic vasculitides [8, 9], with a third study  observing no association. Other studies have reported no FCGR3B CNV associations with Kawasaki disease , antiglomerular basement membrane disease , and Behcet’s disease  nor with vasculitis complicating systemic lupus erythematosus .
The FCGR gene cluster is a complex genomic region, with both SNP and CNV polymorphism. While we were unable to demonstrate an association between FCGR3B copy number and GCA in this study, there are putative links to polymorphism in this region with systemic vasculitides, as SNPs within the FCGR gene cluster have been associated with GCA, Behcet’s diseases and Kawasaki’s disease [22, 23]. However, the high degree of sequence homology between the segmental duplications in the FCGR cluster has hindered sequence annotation and unambiguous SNP mapping in this region, and therefore the interpretation and replication of these studies are unclear.
The strength of our study is the selection of patients with biopsy confirmation of GCA, allowing accurate ascertainment of cases. A limitation of our study is its relatively small sample size. The relatively wide effect size confidence intervals indicate that an association between GCA and either low or high FCGR3B copy number cannot be definitively excluded on the results of this study alone, and future replication studies are required. In general, genetic association studies with GCA have been hindered by the difficulties in collection of DNA samples from elderly patients in an essentially rare, late onset disease. Previously published genetic studies for GCA all have similarly small patient samples sizes, and indeed there is a paucity of different GCA patient cohorts for this type of research. International collaboration will be essential to collect large patient datasets and samples, with prospective recruitment at the time of diagnosis optimal for capturing appropriate samples with accompanying clinical and laboratory data.
The results of this study indicate that FCGR3B copy number variation is not a risk factor for GCA. Larger replication studies will be required to definitively establish any relationship between FCGR3B CNV and GCA and indeed other vasculitides.
Conflict of Interests
The authors have no conflict of interests to declare.
- A. T. Borchers and M. E. Gershwin, “Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment,” Autoimmunity Reviews, vol. 11, no. 6-7, pp. A544–A554, 2012.
- P. Ghosh, F. A. Borg, and B. Dasgupta, “Current understanding and management of giant cell arteritis and polymyalgia rheumatica,” Expert Review of Clinical Immunology, vol. 6, no. 6, pp. 913–928, 2010.
- E. Liozon, B. Ouattara, K. Rhaiem et al., “Familial aggregation in giant cell arteritis and polymyalgia rheumatica: a comprehensive literature review including 4 new families,” Clinical and Experimental Rheumatology, vol. 27, no. 1, pp. S89–S94, 2009.
- C. M. Weyand and J. J. Goronzy, “Functional domains on HLA-DR molecules: implications for the linkage of HLA-DR genes to different autoimmune diseases,” Clinical Immunology and Immunopathology, vol. 70, no. 2, pp. 91–98, 1994.
- C. M. Weyand, K. C. Hicok, G. G. Hunder, and J. J. Goronzy, “The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule,” Journal of Clinical Investigation, vol. 90, no. 6, pp. 2355–2361, 1992.
- P. Stankiewicz and J. R. Lupski, “Structural variation in the human genome and its role in disease,” Annual Review of Medicine, vol. 61, pp. 437–455, 2010.
- F. Nimmerjahn and J. V. Ravetch, “Fcγ receptors as regulators of immune responses,” Nature Reviews Immunology, vol. 8, no. 1, pp. 34–47, 2008.
- L. C. Willcocks, P. A. Lyons, M. R. Clatworthy et al., “Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake,” Journal of Experimental Medicine, vol. 205, no. 7, pp. 1573–1582, 2008.
- M. Fanciulli, P. J. Norsworthy, E. Petretto et al., “FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity,” Nature Genetics, vol. 39, no. 6, pp. 721–723, 2007.
- M. Mamtani, J.-M. Anaya, W. He, and S. K. Ahuja, “Association of copy number variation in the FCGR3B gene with risk of autoimmune diseases,” Genes and Immunity, vol. 11, no. 2, pp. 155–160, 2010.
- J. C. Nossent, M. Rischmueller, and S. Lester, “Low copy number of the Fc-γ receptor 3B gene FCGR3B is a risk factor for primary Sjogren's syndrome,” The Journal of Rheumatology, vol. 39, no. 11, pp. 2142–2147, 2012.
- S. W. Graf, S. Lester, J. C. Nossent et al., “Low copy number of the FCGR3B gene and rheumatoid arthritis: a case-control study and meta-analysis,” Arthritis Research and Therapy, vol. 14, no. 1, article R28, 2012.
- C. McKinney, M. Fanciulli, M. E. Merriman et al., “Association of variation in Fcγ receptor 3B gene copy number with rheumatoid arthritis in Caucasian samples,” Annals of the Rheumatic Diseases, vol. 69, no. 9, pp. 1711–1716, 2010.
- C. McKinney, J. C. A. Broen, M. C. Vonk et al., “Evidence that deletion at FCGR3B is a risk factor for systemic sclerosis,” Genes and Immunity, vol. 13, pp. 458–460, 2012.
- M. Phillipson and P. Kubes, “The neutrophil in vascular inflammation,” Nature Medicine, vol. 17, no. 11, pp. 1381–1390, 2011.
- C. McKinney and T. R. Merriman, “Meta-analysis confirms a role for deletion in FCGR3B in autoimmune phenotypes,” Human Molecular Genetics, vol. 21, no. 10, Article ID dds039, pp. 2370–2376, 2012.
- R. Black, S. Lester, E. Dunstan et al., “Fc-gamma receptor 3B copy number variation is not a risk factor for Behcet's disease,” International Journal of Rheumatology, vol. 2012, Article ID 167096, 4 pages, 2012.
- H. A. Niederer, L. C. Willcocks, T. F. Rayner et al., “Copy number, linkage disequilibrium and disease association in the FCGR locus,” Human Molecular Genetics, vol. 19, no. 16, pp. 3282–3294, 2010.
- W. B. Breunis, E. Van Mirre, J. Geissler et al., “Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B,” Human Mutation, vol. 30, no. 5, pp. E640–E650, 2009.
- X.-J. Zhou, J.-C. Lv, D.-F. Bu et al., “Copy number variation of FCGR3A rather than FCGR3B and FCGR2B is associated with susceptibility to anti-GBM disease,” International Immunology, vol. 22, no. 1, Article ID dxp113, pp. 45–51, 2009.
- H. A. Niederer, M. R. Clatworthy, L. C. Willcocks, and K. G. Smith, “FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus,” Annals of the New York Academy of Sciences, vol. 1183, pp. 69–88, 2010.
- C. C. Khor, S. Davila, W. B. Breunis et al., “Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease,” Nature Genetics, vol. 43, no. 12, pp. 1241–1246, 2011.
- A. W. Morgan, J. I. Robinson, J. H. Barrett et al., “Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis,” Arthritis Research and Therapy, vol. 8, no. 4, article R109, 2006.